Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. (February 2014)

• Record Type: Journal Article
• Authors: Matera, Maria Gabriella; Capuano, Annalisa; Cazzola, Mario
• Is Part Of: Expert review of respiratory medicine. Volume 9:Number 1(2015)
• Page Start: 5
• Page End: 12
• Publication Date: 2014-02
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1586/17476348.2015.986468
• Languages: English
• ISSNs: 1747-6348

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Fluticasone furoate/vilanterol (FF/VI) is a novel inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) fixed dose combination that, by simplifying the dosing schedule, allows, for the first time in a member of the ICS/LABA class, a shift from twice-daily to once-daily treatment. FF/VI is delivered via a novel, single-step activation, multi-dose dry powder inhaler for oral inhalation, Ellipta™. Regrettably, there are no head-to-head trials that have shown superiority in the safety or efficacy of FF versus other ICSs, but evidence shows that VI has a quicker onset of effect versus salmeterol. However, the clinical utility of this effect in a maintenance medication is still questionable. Furthermore, benefits of FF/VI over twice-daily ICS/LABA comparator have not been shown yet and, in addition, its adverse event profile is generally consistent with the known class effects of an ICS/LABA fixed dose combination. In particular, there is an increase in the risk of pneumonia among patients treated with FF/VI relative to VI, mainly among those who benefit most from FF/VI. Nevertheless, the interesting pharmacological profiles of both FF and VI, the possibility that FF/VI can be administered once-daily, and the attractive characteristics of Ellipta™ are important features that could help FF/VI to be a successful combination in the treatment of chronic obstructive pulmonary disease.</p> </abstract>